Chavez-MacGregor M - Search Results

1

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH. Denduluri N, et al. J Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22. J Clin Oncol. 2018. PMID: 29787356

2

HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?

Chavez-MacGregor M, Gonzalez-Angulo AM. Chavez-MacGregor M, et al. Clin Adv Hematol Oncol. 2009 Sep;7(9):591-8. Clin Adv Hematol Oncol. 2009. PMID: 20020671

3

Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.

Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Chavez-Macgregor M, et al. Cancer. 2010 Sep 1;116(17):4168-77. doi: 10.1002/cncr.25296. Cancer. 2010. PMID: 20564153 Free PMC article.

4

Breast cancer, neoadjuvant chemotherapy and residual disease.

Chávez-MacGregor M, González-Angulo AM. Chávez-MacGregor M, et al. Clin Transl Oncol. 2010 Jul;12(7):461-7. doi: 10.1007/s12094-010-0538-0. Clin Transl Oncol. 2010. PMID: 20615822 Review.

5

Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.

Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Chavez-Macgregor M, et al. Cancer. 2012 Jan 15;118(2):326-32. doi: 10.1002/cncr.26144. Epub 2011 May 16. Cancer. 2012. PMID: 21590688 Free PMC article.

6

Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Hernandez-Aya LF, et al. J Clin Oncol. 2011 Jul 1;29(19):2628-34. doi: 10.1200/JCO.2010.32.1877. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606433 Free PMC article.

7

Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Melhem-Bertrandt A, et al. J Clin Oncol. 2011 Jul 1;29(19):2645-52. doi: 10.1200/JCO.2010.33.4441. Epub 2011 May 31. J Clin Oncol. 2011. PMID: 21632501 Free PMC article.

8

Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study.

Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Chavez-MacGregor M, et al. Cancer. 2011 Aug 15;117(16):3641-9. doi: 10.1002/cncr.25972. Epub 2011 Feb 24. Cancer. 2011. PMID: 21656514 Free PMC article.

9

Breast cancer in 2012: New drugs, new knowledge, new targets.

Chavez-MacGregor M, Gonzalez-Angulo AM. Chavez-MacGregor M, et al. Nat Rev Clin Oncol. 2013 Feb;10(2):75-6. doi: 10.1038/nrclinonc.2012.236. Epub 2013 Jan 8. Nat Rev Clin Oncol. 2013. PMID: 23296111 Review. No abstract available.

10

Male breast cancer according to tumor subtype and race: a population-based study.

Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Chavez-Macgregor M, et al. Cancer. 2013 May 1;119(9):1611-7. doi: 10.1002/cncr.27905. Epub 2013 Jan 22. Cancer. 2013. PMID: 23341341 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page